These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29133622)

  • 1. Ceritinib Enhances the Efficacy of Trametinib in
    Verduzco D; Kuenzi BM; Kinose F; Sondak VK; Eroglu Z; Rix U; Smalley KSM
    Mol Cancer Ther; 2018 Jan; 17(1):73-83. PubMed ID: 29133622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
    King JW; Nathan PD
    Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations].
    Haase O; Angün O; Grätz V; Lüttmann N; Neumann A; Zillikens D; Terheyden P
    Hautarzt; 2016 Aug; 67(8):648-52. PubMed ID: 27146499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
    Ming Z; Lim SY; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib.
    Ranzani M; Alifrangis C; Perna D; Dutton-Regester K; Pritchard A; Wong K; Rashid M; Robles-Espinoza CD; Hayward NK; McDermott U; Garnett M; Adams DJ
    Pigment Cell Melanoma Res; 2015 Jan; 28(1):117-9. PubMed ID: 25243813
    [No Abstract]   [Full Text] [Related]  

  • 6. Trametinib in the treatment of melanoma.
    Thota R; Johnson DB; Sosman JA
    Expert Opin Biol Ther; 2015 May; 15(5):735-47. PubMed ID: 25812921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.
    Chung C; Reilly S
    Am J Health Syst Pharm; 2015 Jan; 72(2):101-10. PubMed ID: 25550132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trametinib in metastatic melanoma.
    Chopra N; Nathan PD
    Expert Rev Anticancer Ther; 2015; 15(7):749-60. PubMed ID: 26107021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
    Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
    Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
    Algazi AP; Esteve-Puig R; Nosrati A; Hinds B; Hobbs-Muthukumar A; Nandoskar P; Ortiz-Urda S; Chapman PB; Daud A
    Pigment Cell Melanoma Res; 2018 Jan; 31(1):110-114. PubMed ID: 28921907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
    Phadke MS; Chen Z; Li J; Mohamed E; Davies MA; Smalley I; Duckett DR; Palve V; Czerniecki BJ; Forsyth PA; Noyes D; Adeegbe DO; Eroglu Z; Nguyen KT; Tsai KY; Rix U; Burd CE; Chen YA; Rodriguez PC; Smalley KSM
    Cancer Immunol Res; 2021 May; 9(5):554-567. PubMed ID: 33653716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.
    El Zaoui I; Bucher M; Rimoldi D; Nicolas M; Kaya G; Pescini Gobert R; Bedoni N; Schalenbourg A; Sakina E; Zografos L; Leyvraz S; Riggi N; Rivolta C; Moulin AP
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2764-2772. PubMed ID: 31247083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of MEK inhibitors in the treatment of metastatic melanoma.
    Grimaldi AM; Simeone E; Ascierto PA
    Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
    Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival with MEK inhibition in BRAF-mutated melanoma.
    Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
    N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK; Kim KB
    Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
    Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
    JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.